Analysts Set LivaNova PLC (NASDAQ:LIVN) Price Target at $74.11

Shares of LivaNova PLC (NASDAQ:LIVN) have been given an average recommendation of “Moderate Buy” by the ten research firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $74.7778.

A number of equities research analysts recently weighed in on LIVN shares. KeyCorp began coverage on LivaNova in a research report on Friday, December 19th. They set an “overweight” rating and a $81.00 target price on the stock. Weiss Ratings reiterated a “sell (d+)” rating on shares of LivaNova in a research report on Monday, December 29th. Piper Sandler restated an “overweight” rating and set a $85.00 price objective on shares of LivaNova in a research report on Thursday, February 19th. Barclays upped their target price on LivaNova from $67.00 to $73.00 and gave the company an “equal weight” rating in a research note on Friday. Finally, Wall Street Zen upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 20th.

Institutional Trading of LivaNova

Institutional investors have recently made changes to their positions in the business. Hantz Financial Services Inc. boosted its holdings in LivaNova by 159.9% during the fourth quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock valued at $27,000 after purchasing an additional 267 shares in the last quarter. State of Wyoming bought a new position in shares of LivaNova during the 2nd quarter worth approximately $31,000. EverSource Wealth Advisors LLC lifted its position in shares of LivaNova by 998.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock worth $32,000 after buying an additional 639 shares during the period. Quarry LP acquired a new stake in LivaNova in the 3rd quarter valued at $36,000. Finally, UMB Bank n.a. grew its position in LivaNova by 63.0% in the third quarter. UMB Bank n.a. now owns 792 shares of the company’s stock valued at $41,000 after acquiring an additional 306 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

LivaNova Trading Down 0.6%

Shares of LivaNova stock opened at $70.60 on Thursday. LivaNova has a 1 year low of $32.48 and a 1 year high of $71.92. The company’s fifty day simple moving average is $64.74 and its 200-day simple moving average is $59.10. The company has a market cap of $3.86 billion, a price-to-earnings ratio of -15.83 and a beta of 0.97. The company has a current ratio of 1.36, a quick ratio of 1.12 and a debt-to-equity ratio of 0.29.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings results on Wednesday, February 25th. The company reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.80 by $0.06. LivaNova had a negative net margin of 17.46% and a positive return on equity of 16.54%. The firm had revenue of $360.86 million during the quarter, compared to the consensus estimate of $354.31 million. During the same period in the prior year, the firm earned $0.81 EPS. The business’s revenue was up 12.2% on a year-over-year basis. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. As a group, sell-side analysts expect that LivaNova will post 2.85 EPS for the current year.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.